BF Biosciences Ltd has begun local manufacturing of tirzepatide, bringing one of the world’s most sought-after metabolic drugs into production on Pakistani soil. In a material disclosure to the Pakistan Stock Exchange, the company said it has launched Zeptide (tirzepatide) in an easy-to-use pre-filled syringe, produced at its new European-specification pre-filled syringes facility. The company added that developing Zeptide was included in the utilisation plan for its initial public offering (IPO) proceeds, signalling that funds raised from public investors are now translating into tangible capacity and product roll-out.
Tirzepatide – an injectable therapy that acts as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors – is approved by the United States Food and Drug Administration (FDA) for treating type-2 diabetes and obesity. The formulation is being released in patient-friendly, pre-filled syringes, a format the company says reduces dosing errors. Independent testing of Zeptide’s quality and potency has been conducted at leading mass spectrometry facilities in the US and at a national university in Pakistan, according to the filing. The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account. Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.To read the full article, subscribe and support independent business journalism in Pakistan
